ReviewFuture virology2019
Middle East respiratory syndrome: pathogenesis and therapeutic developments.
Review in Future virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Harnessing immunotherapeutic molecules and diagnostic biomarkers as human-derived adjuvants for MERS-CoV vaccine development.Frontiers in immunology · 2025Review
- No evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model.PloS one · 2024Article
- Exposure to SARS-CoV-2 and Infantile Diseases.Global medical genetics · 2023Article
- Chemokine Levels among Patients with Middle East Respiratory Syndrome Coronavirus Infection.Vaccines · 2023Article
- Airway Epithelial Cell Junctions as Targets for Pathogens and Antimicrobial Therapy.Pharmaceutics · 2022Review
- SARS-CoV-2-Induced Immunosuppression: A Molecular Mimicry Syndrome.Global medical genetics · 2022Article
- Early renal impairment is associated with in-hospital death of patients with COVID-19.The clinical respiratory journal · 2022Article
- Immune Responses in SARS-CoV-2, SARS-CoV, and MERS-CoV Infections: A Comparative Review.International journal of preventive medicine · 2022Review
- From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry.Antibodies (Basel, Switzerland) · 2021Article
- An automated COVID-19 detection based on fused dynamic exemplar pyramid feature extraction and hybrid feature selection using deep learning.Computers in biology and medicine · 2021Article
- Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.Human vaccines & immunotherapeutics · 2021Article
- Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.Life sciences · 2020Review
- When science goes viral: The research response during three months of the COVID-19 outbreak.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Article
- COVID-19 and psoriasis: Should we fear for patients treated with biologics?Dermatologic therapy · 2020Review
- Probiotics at War Against Viruses: What Is Missing From the Picture?Frontiers in microbiology · 2020Review
- A Comprehensive Analysis ofFrontiers in genetics · 2020Article
- A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.Frontiers in immunologyArticle
- A Computational Approach Identified Andrographolide as a Potential Drug for Suppressing COVID-19-Induced Cytokine Storm.Frontiers in immunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first case of Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in the year 2012, which spread rapidly and increased to more than 2200 in 2018. This highly pathogenic virus with high mortality rate is among one of the major public health concerns. Saudi Arabia remains to be the most affected region with the majority of MERS-CoV cases, and currently, no effective drugs and vaccines are available for prevention and treatment. A large amount of information is now available regarding the virus, its structure, route of transmission and its pathophysiology. Therefore, this review summarizes the current understanding of MERS-CoV's pathogenesis, treatment options and recent scientific advancements in vaccine and other therapeutic developments, and the major steps taken for MERS prevention control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.